ABSTRACT
Enzymes are closely associated with the onset and progression of numerous diseases, making enzymes a primary target in innovative drug development. However, the challenge remains in identifying compounds that exhibit potent inhibitory effects on the target enzymes. With the continuous expansion of the total number of natural products and increasing difficulty in isolating and enriching new compounds, traditional high-throughput screening methods are finding it increasingly challenging to meet the demands of new drug development. Virtual screening, characterized by its high efficiency and low cost, has gradually become an indispensable technology in drug development. It represents a prominent example of the integration of artificial intelligence with biopharmaceuticals and is an inevitable trend in the rapid development of innovative drug screening in the future. Therefore, this article primarily focused on systematically reviewing the recent applications of virtual screening technology in the development of enzyme inhibitors and explored the prospects and advantages of using this technology in developing new drugs, aiming to provide essential theoretical insights and references for the application of related technologies in the field of new drug development.
Subject(s)
Artificial Intelligence , Enzyme Inhibitors/pharmacology , High-Throughput Screening Assays , Molecular Docking SimulationABSTRACT
DMNG-3(3ß-Methyl-[2-(4-nitrophenoxy)ethyl]-amino]con-5-enine), is a new and the potentially most potent acetylcholinesterase inhibitor recently obtained from conessine by N-demethylation and nucleophilic substitution reaction. In the present study, a step-down passive avoidance test was used to investigate whether DMNG-3 could modulate impairment of learning and memory induced by scopolamine, and a high performance liquid chromatography(HPLC) method for the determination of DMNG-3 in biological samples was applied to study its pharmacokinetics and tissues distribution. Separation was achieved on C18 column using a mobile phase consisting methanol-water (70:30, v/v) at a flow rate of 1.0ml/min. The intra- and inter-day precisions were good and the RSD was all lower than 1.30%. The mean absolute recovery of DMNG-3 in plasma ranged from 88.55 to 96.45 %. Our results showed oral administration of DMNG-3(10,25,50 mg/kg/day) can significantly improve the latency and number of errors and had a positive effect of improvement of learning and memory in mice in passive avoidance tests. The elimination half-life (T1/2) was 14.07±1.29, 15.87±1.03h, and the total clearance (CL) values were 0.70±0.11, 0.78±0.13 L/h/kg, respectively. The pharmacokinetic studies showed that DMNG-3 has a slowly clearance and large distribution volume in experimental animals, and its disposition is linear over the range of doses tested. The liver, small intestine, stomach, and large intestine were the major distribution tissues of DMNG-3 in mice. It was found that DMNG-3 could be detected in brain, suggesting that DMNG-3 can cross the blood-brain barrier. The present study shows that DMNG-3 can be possible developed as a new drug for the treatment of Alzheimer's disease in the future.
Subject(s)
Avoidance Learning/drug effects , Cholinesterase Inhibitors/pharmacology , Alkaloids/pharmacology , Animals , Antioxidants/metabolism , Antioxidants/pharmacology , Area Under Curve , Cholinergic Antagonists/blood , Cholinergic Antagonists/pharmacology , Cholinesterase Inhibitors/blood , Cholinesterase Inhibitors/chemistry , Dose-Response Relationship, Drug , Flavanones/pharmacology , Half-Life , Male , Memory/drug effects , Mice , Mice, Inbred ICR , Random Allocation , Scopolamine/blood , Scopolamine/pharmacology , Tissue Distribution/drug effectsABSTRACT
<p><b>OBJECTIVE</b>To establish a new gastric bypass animal-model with Goto-Kakizaki rats whose different parts of the small intestine were bypassed while stomach was not bypassed.</p><p><b>METHODS</b>Forty male 3-month-old GK rats were randomly divided into 4 groups: group I (sham operation), group II (duodenum bypassed), group III (jejunum bypassed), group IV (ileum bypassed). Fasting plasma glucose was measured before operation and the 1st, 4th,and 8th week after operation in all the rats, the body weight of all the rats were measured simultaneously.</p><p><b>RESULTS</b>The survival rate of operation for the rats was 95%. Two rats in group IV (died on the first day after operation. The mean fasting plasma glucose concentration of the rats in group II, III, IV (declined obviously 4 weeks after gastric bypass [group II (12.02+/-1.97) vs (6.36+/-0.50) mmol/L, group III (13.42+/-1.66) vs (5.96+/-0.53) mmol/L, group IV (14.32+/-2.82) vs (5.18+/-0.49) mmol/L, all P <0.01], but there were no significant differences among the gastric bypassed groups. The weight of rats in group I, II, III (increased obviously after gastric bypass [group I (253.6+/-9.37) vs (367.0+/-23.70) g, group II (268.2+/-7.95) vs (384.8+/-16.12) g, group III (253.0+/-6.20) vs (323.0+/-16.40) g, all P <0.05] except the rats in group IV ([(262.0+/-13.47) vs(185.8+/-11.56) g].</p><p><b>CONCLUSIONS</b>The mean fasting plasma glucose concentration of the GK rats decreases obviously after gastric bypass through different parts of small intestine. The fasting plasma glucose concentration is not associated with the length of small intestine and body weight.</p>
